Literature DB >> 3970838

Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema.

S Forster, E Ilderton, J F Norris, R Summerly, H J Yardley.   

Abstract

The kinetic properties of phospholipase A2 isolated from single large specimens of normal human epidermis and 'uninvolved' (lesion-free) psoriatic epidermis were determined. The enzymes from the two sources behaved identically with respect to changes in protein concentration, Ca2+ concentration and pH, but the enzymes responded differently to changes in substrate concentration. Furthermore, the specific activity of the enzyme derived from lesion-free psoriatic epidermis was higher than that from normal epidermis under all conditions used. Increased specific activity of the enzyme in the lesion-free epidermis was also found when biopsy specimens taken from thirty-five patients with psoriasis vulgaris at varying severity were compared with biopsies of normal epidermis from thirty-one control volunteers (P less than 0.001). Mixing experiments, in which homogenates of lesion-free psoriatic epidermis and control epidermis were combined, suggested that the relatively low activity of the enzyme in normal epidermis was due to the presence of an inhibitor. As the activity of the enzyme was not elevated in the lesion-free epidermis from twelve cases of eczema, which is also an inflammatory condition of the epidermis and superficial dermis, it is suggested that the raised phospholipase A2 activity demonstrated in the lesion-free epidermis of psoriasis may play an important role in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970838     DOI: 10.1111/j.1365-2133.1985.tb00077.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

1.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

Authors:  Preethi Badrinarayan; P Srivani; G Narahari Sastry
Journal:  J Mol Model       Date:  2010-06-23       Impact factor: 1.810

2.  Immunohistochemical localization of lipocortins in normal and psoriatic human skin.

Authors:  K Ikai; K Shimizu; Y Ando; F Furukawa; S Imamura; R Kannagi
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

3.  Sexual dimorphism in the hypothalamo-pituitary-adrenal (HPA) axis and TNFalpha responses to phospholipase A2-related neurotoxin (from crotalus durissus terrifcus) challenge.

Authors:  A N Chisari; R C Gaillard; A Giovambattista; J Piermaría; E Spinedi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

4.  Swine as a model of skin inflammation. Phospholipase A2-induced inflammation.

Authors:  X Nair; D Nettleton; D Clever; K M Tramposch; S Ghosh; R C Franson
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

5.  Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue.

Authors:  S Andersen; W Sjursen; A Laegreid; G Volden; B Johansen
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

6.  Monohydroxy fatty acids esterified to phospholipids are decreased in lesional psoriatic skin.

Authors:  B Grøn; L Iversen; V Ziboh; K Kragballe
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

7.  Characterization and pharmacological modulation of soluble phospholipase A2 generated during glycogen-induced rat peritonitis.

Authors:  L A Marshall; J Murphy; L Marinari; J Chang
Journal:  Agents Actions       Date:  1992-09

8.  Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate.

Authors:  D S Grass; R H Felkner; M Y Chiang; R E Wallace; T J Nevalainen; C F Bennett; M E Swanson
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

9.  Lysophosphatidylcholine: a chemoattractant to human T lymphocytes.

Authors:  A K Ryborg; B Deleuran; K Thestrup-Pedersen; K Kragballe
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 10.  Topical glucocorticoids and the skin--mechanisms of action: an update.

Authors:  A Ahluwalia
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.